What is HC Wainwright’s Estimate for CMPS FY2030 Earnings?

Compass Pathways PLC Sponsored ADR (NASDAQ:CMPS) – Research analysts at HC Wainwright issued their FY2030 earnings per share estimates for shares of Compass Pathways in a research report issued to clients and investors on Monday, March 2nd. HC Wainwright analyst P. Trucchio expects that the company will post earnings of $6.46 per share for the year. HC Wainwright has a “Buy” rating and a $70.00 price target on the stock. The consensus estimate for Compass Pathways’ current full-year earnings is ($2.33) per share.

CMPS has been the topic of several other research reports. Lifesci Capital raised shares of Compass Pathways to a “strong-buy” rating in a report on Thursday, February 12th. Royal Bank Of Canada upped their price objective on shares of Compass Pathways from $21.00 to $22.00 and gave the stock an “outperform” rating in a research note on Wednesday, February 18th. Canaccord Genuity Group raised their price objective on shares of Compass Pathways from $15.00 to $20.00 and gave the stock a “buy” rating in a report on Wednesday, February 18th. Compass Point set a $15.00 target price on shares of Compass Pathways in a research note on Thursday, February 12th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Compass Pathways in a report on Wednesday, January 21st. One equities research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Compass Pathways currently has a consensus rating of “Moderate Buy” and an average price target of $22.13.

Compass Pathways Stock Performance

Compass Pathways stock opened at $7.05 on Wednesday. The firm has a market capitalization of $676.94 million, a P/E ratio of -2.59 and a beta of 1.90. The stock has a fifty day moving average price of $6.99 and a two-hundred day moving average price of $6.12. Compass Pathways has a 52-week low of $2.25 and a 52-week high of $8.90. The company has a debt-to-equity ratio of 0.55, a current ratio of 1.23 and a quick ratio of 1.23.

Institutional Trading of Compass Pathways

Hedge funds and other institutional investors have recently modified their holdings of the stock. RTW Investments LP lifted its holdings in Compass Pathways by 0.6% during the 4th quarter. RTW Investments LP now owns 8,757,390 shares of the company’s stock worth $60,426,000 after buying an additional 50,000 shares in the last quarter. Nantahala Capital Management LLC increased its stake in shares of Compass Pathways by 47.7% in the 2nd quarter. Nantahala Capital Management LLC now owns 4,179,930 shares of the company’s stock valued at $11,704,000 after buying an additional 1,350,698 shares during the period. Millennium Management LLC raised its position in shares of Compass Pathways by 39.9% during the third quarter. Millennium Management LLC now owns 2,715,872 shares of the company’s stock worth $15,562,000 after acquiring an additional 774,090 shares during the last quarter. Toronto Dominion Bank raised its position in shares of Compass Pathways by 152.9% during the fourth quarter. Toronto Dominion Bank now owns 2,529,013 shares of the company’s stock worth $17,447,000 after acquiring an additional 1,529,013 shares during the last quarter. Finally, ARK Investment Management LLC lifted its stake in shares of Compass Pathways by 1.6% during the fourth quarter. ARK Investment Management LLC now owns 2,156,012 shares of the company’s stock valued at $14,876,000 after acquiring an additional 34,894 shares during the period. Institutional investors and hedge funds own 46.19% of the company’s stock.

About Compass Pathways

Compass Pathways (NASDAQ: CMPS) is a clinical-stage biotechnology company focused on the development and commercialization of psilocybin therapy for mental health disorders. Founded in 2016 and headquartered in London with additional offices in the United States, Compass Pathways is pioneering the use of synthetic psilocybin combined with psychotherapy to address treatment-resistant depression. The company’s flagship program is a Phase IIb clinical trial evaluating COMP360, its proprietary psilocybin formulation, which has received Breakthrough Therapy designation from the U.S.